CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy
Sign Up to like & getrecommendations! Published in 2018 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-018-4876-x
Abstract: PurposeTamoxifen is frequently prescribed to prevent breast cancer recurrence. Tamoxifen is a prodrug and requires bioactivation by CYP2D6. Tamoxifen use is often limited by adverse effects including severe hot flashes. There is paucity of prospectively… read more here.
Keywords: flash severity; endoxifen; tamoxifen therapy; hot flash ... See more keywords